98716 Geschwenda, de
+49 (89) 12142-7036
New cooperation links diagnostics and therapy with the goal of better stroke prophylaxisMunich/Pirmasens, )
SRA technology offers the possibility of detecting patients with pVHF early, quickly and reliably in order to treat this cardiac arrhythmia adequately. In patients who have already suffered a stroke, the technology makes it easier to identify atrial fibrillation as the cause. It can thus help to prevent secondary events.
In Germany, about 200,000 first-time and 66,000 repeated strokes1 occur annually, with about one in five strokes being due to atrial fibrillation2. 13 percent of people over 65 years of age in Germany are currently routinely screened for VHF.3 In addition, more than half of all patients with VHF are unremarkable or have only minimal symptoms.4 In addition, the majority of patients are not diagnosed with VHF until the time of the stroke.5
"In addition to the development of modern drugs for stroke prevention, we are promoting the development and use of innovative technologies that improve atrial fibrillation screening to close gaps in care for patients with undiagnosed and undertreated atrial fibrillation," emphasizes Dr. Michael Krekler, Medical Director Cardiovascular Diseases at Bristol-Myers Squibb, emphasizing the importance of precise diagnostics in stroke prevention. "We are convinced that the cooperation with Bristol-Myers Squibb will enable us to better integrate our technology into routine care in order to reduce the risk of strokes," explains Albert Hirtz, Managing Director at apoplex medical technologies.
SRA technology uses pseudonymised data from ECG derivatives to calculate the risk of atrial fibrillation in an automated, three-step procedure. In this way, the attending physician receives the result of the risk calculation in the form of an analysis report within a few minutes - by e-mail or via a separate website. If VHF is diagnosed, non-vitamin K-dependent oral anticoagulants are used in stroke prophylaxis in accordance with national and international guidelines.2,6
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company dedicated to the discovery, development and use of innovative drugs to help patients fight serious diseases. Further information is available at www.bms.com/de or www.bms.com.
About apoplex medical technologies
apoplex medical technologies GmbH was founded in 2004 in Pirmasens, West Palatinate, and specializes in new and innovative technology products for stroke prevention in worldwide use in the field of medical technology. The subsidiary of Geratherm Medical AG focuses on easy-to-use and efficient methods of so-called patient screening using medical technology applications to prevent strokes and vascular dementia. The SRA (Stroke Risk Analysis) procedure is the first viable screening procedure for paroxysmal atrial fibrillation. It is available in variants for stroke units and for use in medical practices. apoplex medical technologies is supported by an extensive academic and clinical network that complements its own core competencies in mathematics, physics and medicine. Further information is available at www.apoplexmedical.com
1. Heuschmann PU et al. Akt Neurol 2010; 37: 333340.
2. Kirchhof P et al. Eur Heart J. 2016;37:2893-2962
3. Economist Intelligence Unit. Preventing Stroke: Uneven Progress Report. 21. September 2017
4. Huisman MV et al. J Am Coll Cardiol 2017;69:777-785
5. Blackshear J et al. Ann Thorac Surg 1996;61:755-9
6. Deutsche Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e.V. (2017) ESC Pocket Guidelines. Management von Vorhofflimmern, Version 2016
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an firstname.lastname@example.org.